Trial · NCT05339087
Registered outcomes31
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 31
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of Pulmonary Vascular Resistance (PVR) | baseline, 24 weeks | Change in pulmonary hemodynamics assessed by right heart catheterization |
| Secondary | Change of Cardiac Index (CI) at Rest From Baseline at 24 Weeks | baseline, 24 weeks | Change in pulmonary hemodynamics assessed by right heart catheterization |
| Secondary | Change of Total Pulmonary Resistance (TPR) From Baseline at 24 Weeks | baseline, 24 weeks | Change in Pulmonary hemodynamics assessed by right heart catheterization Hierarchical testing of secondary endpoints stopped after first step. |
| Secondary | Change of Diffusion Capacity of the Lung (DLCO) From Baseline at 24 Weeks | baseline, 24 weeks | Change assessed by lung function tests. Hierarchical testing of secondary endpoints stopped after first step. |
| Secondary | Change in 6-minute Walking Distance (6MWD) | baseline, 24 weeks | Change in exercise capacity assessed by 6-minute walking distance test Hierarchical testing of secondary endpoints stopped after first step. |
| Secondary | Change of World Health Organization- Functional Class (WHO-FC) From Baseline at 24 Weeks | baseline, 24 weeks | Change of WHO functional class, change score The World Health Organization (WHO) functional class (FC) describes the severity of pulmonary hypertension (PH) symptoms. FC I is considered the mildest and FC IV the most severe form of PH. |
| Other | Change of World Health Organization- Functional Class (WHO-FC) From Baseline at 12 Weeks | baseline, 12 weeks | Change of WHO functional class, change score The World Health Organization (WHO) functional class (FC) describes the severity of pulmonary hypertension (PH) symptoms. FC I is considered the mildest and FC IV the most severe form of PH. |
| Other | Change in Quality of Life (QoL) From Baseline at 24 Weeks | baseline, 24 weeks | Quality of Life (QoL) was assessed using the Short Form (SF) 36-questionnaire. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale, i.e. a score of 0 is equivalent to maximum disability and a score of 100 is equivalent to no disability. Sections: vitality; physical functioning; bodily pain; general health perceptions; physical role functioning; emotional role functioning; social role functioning; mental health. Two summation scores, physical and mental summation score, were calculated |
| Other | Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline at 24 Weeks | baseline, 24 weeks | Lung function and lung diffusing capacity |
| Other | Change in Total Lung Capacity (TLC) From Baseline at 24 Weeks | baseline, 24 weeks | Lung function and lung diffusing capacity |
| Other | Change in Diffusing Capacity of the Lung (DLCO) | baseline, 24 weeks | Lung function and lung diffusing capacity |
| Other | Change in Systolic Pulmonary Arterial Pressure (sPAP) From Baseline at 24 Weeks | baseline, 24 weeks | Change in systolic pulmonary arterial pressure (sPAP) from baseline at 24 weeks assessed by echocardiography |
| Other | Change in Right Ventricular Area (RV-area) From Baseline at 24 Weeks | baseline, 24 weeks | Change in right ventricular area (RV-area) from baseline at 24 weeks assessed by echocardiography |
| Other | Change in Right Atrial Area (RA-area) From Baseline at 24 Weeks | baseline, 24 weeks | Change in right atrial area (RA-area) from baseline at 24 weeks assessed by echocardiography |
| Other | Change in Tricuspid Annular Plane Systolic Excursion (TAPSE) From Baseline at 24 Weeks | baseline, 24 weeks | Change in tricuspid annular plane systolic excursion (TAPSE) from baseline at 24 weeks assessed by echocardiography |
| Other | Change in Left Ventricular Eccentricity Index (LV-EI) From Baseline at 24 Weeks | baseline, 24 weeks | Change in left ventricular eccentricity index (LV-EI) from baseline at 24 weeks assessed by echocardiography. LV-EI is the ratio of septical-parallel to septical-perdendicular left ventricular diameters in parasternal short-axis view; normal = 1, increased (≥ 1.1) indicates right ventricular pressure/volume overload |
| Other | Change in N-terminal Prohormone of Brain Natriuretic Peptide (NT-pro BNP) From Baseline at 12 Weeks | baseline, 12 weeks | blood analysis |
| Other | Change in N-terminal Prohormone of Brain Natriuretic Peptide (NT-pro BNP) From Baseline at 24 Weeks | baseline, 24 weeks | blood analysis |
| Other | Change in Oxygen Partial Pressure (PaO2) From Baseline at 24 Weeks | baseline, 24 weeks | Change in oxygen partial pressure (PaO2) from baseline at 24 weeks assessed by blood gas analysis |
| Other | Change in Carbon Dioxide Partial Pressure (PCO2) | baseline, 24 weeks | blood gas analysis |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05339087/registered